HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis

HSCT from an unrelated HLA-mismatched donor (MMUD) is one of the alternatives where HLA-matched not found. The aim this study was to compare GvHD prophylaxis with anti-thymocyte globulin (ATG) vs. post-transplant cyclophosphamide (PT-Cy). Thirty-nine adult patients were uniformly treated rabbit ATG-Cy-A-MTX and peripheral blood stem cell (PBSC) 40 PT-Cy-MMF-tacrolimus PBSC. This retrospective registered at ClinicalTrials.gov NCT04598789. Three-year overall survival 42% 64% for ATG PT-Cy (p < 0.0005), three-year treatment-related mortality (TRM) 36% 8% = 0.0033) relapse incidence (RI) 15% 28% NS), respectively. incidences day-100 graded II–IV III–IV 39% 7% 0.0006) 11% 0% 0.04), respectively, whereas cGvHD 48% 13% We able show how can reduce GvHDs TRM in adults, but remains issue.